The use of neoadjuvant therapy for resectable locally advanced thoracic esophageal squamous cell carcinoma in an analysis of 5016 patients from 305 designated cancer care hospitals in Japan
- 293 Downloads
Recent studies have shown the benefits of neoadjuvant therapy with chemotherapy or chemoradiotherapy for resectable locally advanced thoracic esophageal squamous cell carcinoma (ESCC). The aim of our study was to elucidate the use of neoadjuvant therapy for thoracic ESCC in Japan.
Data on patients with stage IB–III thoracic ESCC were retrieved from the national database of hospital-based cancer registries combined with claims data between 2012 and 2013. These data were analyzed using a mixed-effect logistic regression analysis, with a focus on exploring patterns in the first-line treatment for ESCC, including proportion of patients who received neoadjuvant therapy, and investigating the hospital characteristics and patient factors associated with the use of neoadjuvant therapy.
Of the 5016 patients with stage IB–III thoracic ESCC at the 305 participating hospitals, 34.2% received neoadjuvant therapy (neoadjuvant chemotherapy, 29.5%; neoadjuvant chemoradiotherapy, 4.7%). The therapy was less likely to be administered to older patients (≤64 years, 48.8%; 65–70 years, 42.0%; 70–75 years, 33.9%; 75–80 years, 22.2%; 80–85 years, 3.8%; ≥85 years, 1.4%) and at hospitals with a low volume of patients (very high, 42.1%; high, 37.5%; low, 30.7%; and very low, 26.4%). This trend was confirmed by regression analysis.
Based on our results, in Japan, relatively few patients with resectable locally advanced thoracic ESCC receive neoadjuvant therapy, with older patients and patients at lower volume hospitals being less likely than other patients to receive the neoadjuvant therapy. We recommend that the process of treatment decision-making be assessed at both the patient and hospital levels so that patients can consider various treatment options, including neoadjuvant therapy with surgery in Japan.
KeywordsEsophageal cancer Practice patterns Healthcare inequalities Registries Age Hospital volume
We thank Kaoru Konno for her technical assistance for this project, as well as the participating hospitals that submitted insurance claim data. This work was supported by the National Cancer Center Research and Development Programs (Grant Number 28–A–21).
Compliance with ethical standards
Conflict of interest
No conflict of interest.
- 1.Ferlay J SI, Ervik M, Dikshit R, et al. (2013) GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11. http://globocan.iarc.fr. Accessed July 2016
- 3.Ando N, Kato H, Igaki H, et al. (2012) A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus (JCOG9907). Ann Surg Oncol 19:68–74CrossRefPubMedGoogle Scholar
- 5.The Japan Esophageal Society (2012) Guidelines for diagnosis and treatments of esophageal cancer. Kanehara Co. Ltd, Tokyo (in Japanese)Google Scholar
- 6.The National Comprehensive Cancer Network (2016) Esophageal and esophagogastric junction cancers, ver 2, 2016. https://www.nccn.org/professionals/physician_gls/pdf/esophageal.pdf. Accessed Sept 2016
- 16.Cancer Information Surveillance Division, Center for Cancer Control and Information Services. National Cancer Center (2016) the Report of Hospital-Based Cancer Registry from Designated Cacner Center Hospitals in Japan 2014. http://ganjoho.jp/data/reg_stat/statistics/brochure/2014_report.pdf. Accessed April 2017 (in Japanese)
- 19.Nakamura K, Kato K, Igaki H, et al. (2013) Three-arm phase III trial comparing cisplatin plus 5-FU (CF) versus docetaxel, cisplatin plus 5-FU (DCF) versus radiotherapy with CF (CF-RT) as preoperative therapy for locally advanced esophageal cancer (JCOG1109, NExT study). Jpn J Clin Oncol 43:752–755CrossRefPubMedGoogle Scholar
- 22.Bradley JD, Paulus R, Graham MV, et al. (2005) Phase II trial of postoperative adjuvant paclitaxel/carboplatin and thoracic radiotherapy in resected stage II and IIIA non-small-cell lung cancer: promising long-term results of the Radiation Therapy Oncology Group—RTOG 9705. J Clin Oncol 23:3480–3487CrossRefPubMedGoogle Scholar
- 24.Lester SC, Lin SH, Chuong M, et al. (2017) A multi-institutional analysis of trimodality therapy for esophagus cancer in elderly patients. Int J Radiat Oncol Biol Phys 98:820–828Google Scholar
- 40.World Health Organization (WHO) and Ministry of Health, Labour and Welfare, Japan (2012) Health Service Delivery Profile Japan 2012. http://www.wpro.who.int/health_services/service_delivery_profile_japan.pdf. Accessed July 2017
- 45.Center for Cancer Control and Information Services, National Cancer Center (2015) Current cancer statistics. http://ganjoho.jp/reg_stat/statistics/stat/summary.html. Accessed Jan 2017 (in Japanese)